Q1 EPS Forecast for Nektar Therapeutics Raised by Analyst

Nektar Therapeutics (NASDAQ:NKTR) – Equities researchers at Zacks Research raised their Q1 2025 EPS estimates for shares of Nektar Therapeutics in a research report issued on Wednesday, January 29th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings per share of ($0.21) for the quarter, up from their prior forecast of ($0.22). The consensus estimate for Nektar Therapeutics’ current full-year earnings is ($0.72) per share. Zacks Research also issued estimates for Nektar Therapeutics’ Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.84) EPS, Q1 2026 earnings at ($0.21) EPS, Q2 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.22) EPS and FY2026 earnings at ($0.86) EPS.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. Nektar Therapeutics had a negative net margin of 180.70% and a negative return on equity of 173.28%. The firm had revenue of $24.12 million during the quarter, compared to analyst estimates of $15.54 million. During the same quarter last year, the business earned ($0.19) EPS.

Several other research analysts have also recently issued reports on NKTR. HC Wainwright reiterated a “buy” rating and set a $6.50 target price on shares of Nektar Therapeutics in a report on Monday, January 13th. B. Riley initiated coverage on shares of Nektar Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $4.00 price objective on the stock. Finally, Piper Sandler initiated coverage on shares of Nektar Therapeutics in a research note on Monday, November 4th. They issued an “overweight” rating and a $7.00 price objective for the company. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Nektar Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $4.08.

Nektar Therapeutics Stock Performance

Shares of NASDAQ:NKTR opened at $0.81 on Monday. The firm has a market cap of $149.21 million, a PE ratio of -0.96 and a beta of 0.58. The firm’s 50 day simple moving average is $0.98 and its 200-day simple moving average is $1.16. Nektar Therapeutics has a one year low of $0.54 and a one year high of $1.93.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in NKTR. Peapod Lane Capital LLC acquired a new position in Nektar Therapeutics during the 4th quarter worth approximately $1,030,000. Moloney Securities Asset Management LLC grew its stake in shares of Nektar Therapeutics by 42.4% during the fourth quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 14,895 shares in the last quarter. SG Americas Securities LLC increased its holdings in Nektar Therapeutics by 12.2% in the fourth quarter. SG Americas Securities LLC now owns 107,318 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 11,681 shares during the last quarter. HB Wealth Management LLC raised its stake in Nektar Therapeutics by 44.0% in the fourth quarter. HB Wealth Management LLC now owns 64,100 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 19,600 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Nektar Therapeutics by 197.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 913,300 shares of the biopharmaceutical company’s stock worth $1,187,000 after buying an additional 606,057 shares during the last quarter. Institutional investors and hedge funds own 75.88% of the company’s stock.

Insider Buying and Selling at Nektar Therapeutics

In related news, insider Jonathan Zalevsky sold 51,115 shares of the business’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $0.94, for a total value of $48,048.10. Following the sale, the insider now directly owns 326,904 shares in the company, valued at approximately $307,289.76. The trade was a 13.52 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark Andrew Wilson sold 33,402 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $0.90, for a total transaction of $30,061.80. Following the completion of the transaction, the insider now owns 351,892 shares in the company, valued at approximately $316,702.80. This represents a 8.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 155,575 shares of company stock valued at $149,878 over the last quarter. 3.71% of the stock is currently owned by insiders.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.